随着人口老龄化，骨质疏松症已成为严峻的公共卫生问题。绝经后妇女骨质疏松症发生率高，因此，研究治疗本病的安全、有效药物是医学上的难点及热点。本课题组前期发现古方青娥丸能提高骨质疏松症患者骨密度，其机制与其能调控Wnt/β-Catenin信号通路，上调骨保护蛋白表达有关。新近有学者发现Wnt信号通路抑制因子DKK-1与骨量丢失疾病关系最为密切。近期预实验显示：青娥丸可下调骨质疏松模鼠骨折骨痂DDK-1的表达，促进骨愈合。由此我们推测青娥丸治疗绝经后骨质疏松症疗效机理之一，可能与其调控Wnt-DDK-1信号通路有关。本项目拟采用流式细胞术、免疫印迹、酶联免疫吸附试验等技术，动态观察青娥丸治疗绝经后骨质疏松症患者过程中，DKK-1浓度或活性变化；并实施相应的动物实验，体外细胞学研究，对比分析青娥丸是否可通过调控该信号通路治疗绝经后骨质疏松症，以期明确该方的作用靶点，为其推广应用提供理论依据。

With the advent of aging society, osteoporosis has become an increasingly serious public healtth preoblem in the current world. The high incidence of post-menopause women suffer from osteoporsis,so searching for safe and effective durg is difficulty and hot in the domain of medicine.Our previous study confirmed that the effect of Qing E pill,a traditional ancient formula,in treating postmenopausal osteoporosis was notable and this therapeutic effect is associated with it can regulate the levels of plasma Wnt/β-catenin - OPG singaling pathway. Recently,some scholars report that the Wnt-DDK1 singaling pathway plays an important role in Bone loss disease. Our pre-tests showed that this traditional ancient formula could down-regulate the expression of DDK-1 in callus of ovariectomized rats with osterporosis fracture and promoting fracture healing. Therefore,we infer that regulating Wnt-DDK-1 signaling pathway perphaps is one of the most important mechanisms of Qinge pill to treat postmenopausal osteoporosis.Based on this point, in the present study,flow cytometry, Western blot, ELISA techniques and other experimental methods will be used for dynamic observing DKK-1 concentration or activity changes of patients with postmenopausal osteoporosis before and after Qing'e Pill treatment; and implement appropriate animal experiments, in vitro cytological studies for identifying Qinge pills action target and providing theoretical basis for actual application of the traditional ancient formula.